We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 238.00
Bid: 237.50
Ask: 238.50
Change: 0.50 (0.21%)
Spread: 1.00 (0.421%)
Open: 239.00
High: 239.00
Low: 236.50
Prev. Close: 237.50
AGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Factsheet

8 Feb 2024 14:13

RNS Number : 5347C
AVI Global Trust PLC
08 February 2024

AVI GLOBAL TRUST PLC

Monthly Update

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 31 January 2024.

This Monthly Newsletter is available on the Company's website at:

https://www.assetvalueinvestors.com/content/uploads/2024/02/AGT-JANUARY-2024.pdf

Performance Total Return

This investment management report relates to performance figures to 31 January 2024.

Total Return (£)

Month

Calendar Yr

to date

1Y

3Y

5Y

10Y

AGT NAV

1.2%

1.2%

13.5%

36.2%

75.6%

169.7%

MSCI ACWI

0.7%

0.7%

10.9%

28.8%

67.6%

189.9%

MSCI ACWI Ex US

-0.9%

-0.9%

2.4%

11.5%

33.9%

94.9%

Manager's Comment

AVI Global Trust (AGT)'s NAV increased +1.2% in January.

Godrej Industries (+57bps) was the standout contributor, with the shares up +21% over the month as the discount continues to narrow. Apollo (+38bps), Schibsted (+33bps) and FEMSA (+24bps) were also strong performers. Oakley Capital Investments detracted -54bps as the shares declined -7%, and Aker shaved off -47bps with the shares -6%.

Shares in Christian Dior, the mono-holding company through which Bernard Arnault controls LVMH, rose +4% during a month in which LVMH reported full year results.

When we last wrote about Christian Dior in January 2023 there was near universal excitement about the prospects for the luxury goods sector, and the impact of the "re-opening" of China's economy on growth. In the spring of 2023 LVMH rose to become the first $500bn market cap company in Europe. Shortly after this we sold ~1/3rd of our position (in Christian Dior) at a price of ?809. As 2023 progressed, growth in China underwhelmed and concerns mounted over a slowdown in luxury spending following the elevated global demand observed during COVID. This allowed us to modestly add back to the position at an average price of ?678 during the latter half of 2023. The shares currently trade at ?737.

The consensus view toward luxury goods today is much more sceptical than it was a year ago. However, we believe LVMH is well positioned both in the nearer term and longer term.

We wrote last year that Louis Vuitton was underearning, with high levels of "investment" in operating expenses depressing earnings in the near-term but building brand desirability and entrenching dominance. The benefits of this were evident in the 2023 full year results, with sales growing +13% organically and operating profit increasing by +8%. Importantly, the scaled cost structure offers considerable flexibility, with sales and marketing expenditure flat year on year in the second half of the year, having grown +26% in the first half.

Smaller mono-brands that have underinvested and have less flexible cost structures will likely find the path to a post COVID normalised world more challenging, with LVMH growing at roughly twice the rate of the overall industry in Q4. It is our contention that such outperformance will likely endure, given the considerable scale advantages in an industry with relatively high fixed costs. In previous cycles LVMH has emerged stronger - the bigger get bigger - and we expect this to be the same once again, with optionality around countercyclical M&A given LVMH's pristine balance sheet.

Looking further ahead we believe LVMH offers exposure to an irreplicable collection of competitively advantaged brands operating in a sector with attractive long-term growth prospects and strong underlying economics, returns on capital and cash generation.

These advantages and attractions do not seem to excessively reflect in LVMH's valuation. The shares trade at a 17x 2024 EV/EBIT and a 2024 FCF yield of ~4.5%. In the context of other luxury goods companies this is a middle of the pack valuation for a company that has consistently performed ahead of the pack and reflects a considerable conglomerate discount (34% on our numbers).

Returning to Christian Dior, the shares currently trade an 18% discount to NAV. At some point of the family's choosing the mono-hold co structure will likely be collapsed, providing an additional kicker to returns, which have and will be principally a function of NAV growth. To date the investment in Christian Dior has generated an ROI and IRR of +110% and +27%, respectively.

Portfolio activity

During the month we fully exited our investment in Pershing Square Holdings (PSH). The position had been held since 2017 and generated an IRR of +21% vs. +9% for the MSCI ACWI ex-US. With our universe throwing up some of the most attractive opportunities we have seen in many years, we began reducing our shareholding in PSH over 2023 to fund investments where we see greater scope for attractive event-driven returns over shorter time-frames.

One such example is our position in Bollore, which shares with PSH a common exposure in Universal Music Group (directly via Bollore's 18% stake and indirectly via Vivendi's 10% stake), and which we added to using a portion of the sale proceeds from PSH.

Since we wrote the company up in the October newsletter it has been announced that Vivendi - the media conglomerate in which Bollore owns just shy of a 30% stake - will be broken up into four different businesses in an effort to reduce the sum-of-the-parts discount at which it trades.

This is interesting for several reasons. Firstly, this is the only time a Bollore company has openly and proactively tried to address the issue of a discount. Secondly, and more tangibly, this raises the prospects of further tender offers and simplifications higher up the Bollore structure.

It had previously been our expectation that some or all Bollore's (soon to be) ?6bn net cash balance would be deployed into Vivendi shares. However, buybacks and tender offers seem probable in the absence of this. The 10% April 2023 tender offer at ?6 per share (inclusive of the ?0.25 of contingent consideration in anticipation of the closing of the sale of Bollore Logistics) only saw 34% uptake. We believe future tender offers will likely be struck at a meaningfully higher price (with the NAV up +11% in the interim) and view this as a near-term catalyst for the shares. Beyond that there is scope for further transactions in one of Europe's last byzantine corporate structures. We believe it is an interesting time to align capital with a flush Vincent Bollore and that the market is under-pricing the potential for value to be unlocked.

As well as this we have been busy elsewhere in the portfolio. In recent months we have added to existing positions in News Corp and D'Ieteren. We have slowly started to build a position in a UK conglomerate and have built a starter position in a UK-listed special situation that we came across via one our existing investments. As well as this we have established new positions in two London-listed closed-end funds.

Contributors / Detractors (in GBP)

Largest Contributors

1- month contribution

bps

% Weight

Godrej Industries

57

3.1

Apollo Global

38

5.1

Schibsted ASA 'B'

33

5.5

FEMSA

24

6.1

KKR

22

5.2

Largest Detractors

1- month contribution

bps

% Weight

Oakley Capital Investments

-54

7.0

Aker ASA

-47

5.2

Molten Ventures

-26

1.6

Hipgnosis Songs

-20

4.7

Frasers Group

-14

1.5

Link Company Matters Limited

Corporate Secretary

8 February 2024

LEI: 213800QUODCLWWRVI968

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DOCMZGGZDRZGDZM
Date   Source Headline
29th Apr 20241:34 pmRNSNet Asset Value(s)
26th Apr 202412:06 pmRNSNet Asset Value(s)
25th Apr 20241:57 pmRNSNet Asset Value(s)
24th Apr 202412:34 pmRNSNet Asset Value(s)
23rd Apr 20241:00 pmRNSNet Asset Value(s)
22nd Apr 202412:54 pmRNSNet Asset Value(s)
19th Apr 20245:35 pmRNSTransaction in Own Shares
19th Apr 20243:39 pmRNSNet Asset Value(s)
19th Apr 20247:00 amRNSCompliance with Market Abuse Regulation
18th Apr 20245:40 pmRNSTransaction in Own Shares
18th Apr 202412:18 pmRNSNet Asset Value(s)
17th Apr 202412:24 pmRNSNet Asset Value(s)
16th Apr 202412:31 pmRNSNet Asset Value(s)
15th Apr 202412:44 pmRNSNet Asset Value(s)
12th Apr 20245:30 pmRNSTransaction in Own Shares
12th Apr 20242:09 pmRNSNet Asset Value(s)
11th Apr 20245:49 pmRNSTransaction in Own Shares
11th Apr 202412:59 pmRNSNet Asset Value(s)
10th Apr 20245:44 pmRNSTransaction in Own Shares
10th Apr 20241:01 pmRNSNet Asset Value(s)
9th Apr 20245:40 pmRNSTransaction in Own Shares
9th Apr 20243:48 pmRNSMonthly Factsheet
9th Apr 202412:20 pmRNSNet Asset Value(s)
9th Apr 202411:56 amRNSDirector/PDMR Shareholding
8th Apr 20244:58 pmRNSDirector/PDMR Shareholding
8th Apr 202412:58 pmRNSNet Asset Value(s)
8th Apr 202412:53 pmRNSAppointment of Corporate Broker
8th Apr 202412:39 pmRNSListing Rule 15.6.8
5th Apr 20241:57 pmRNSNet Asset Value(s)
4th Apr 20245:32 pmRNSTransaction in Own Shares
4th Apr 20241:13 pmRNSNet Asset Value(s)
3rd Apr 20245:32 pmRNSTransaction in Own Shares
3rd Apr 20242:28 pmRNSNet Asset Value(s)
3rd Apr 20247:00 amRNSKepler Trust Intelligence: New Research
2nd Apr 20245:30 pmRNSTransaction in Own Shares
2nd Apr 20244:32 pmRNSNet Asset Value(s)
2nd Apr 202412:31 pmRNSTotal Voting Rights
28th Mar 20245:32 pmRNSTransaction in Own Shares
28th Mar 20242:08 pmRNSNet Asset Value(s)
27th Mar 20245:48 pmRNSTransaction in Own Shares
27th Mar 20243:27 pmRNSNet Asset Value(s)
26th Mar 20245:23 pmRNSTransaction in Own Shares
26th Mar 20242:12 pmRNSNet Asset Value(s)
25th Mar 20245:29 pmRNSTransaction in Own Shares
25th Mar 20242:00 pmRNSNet Asset Value(s)
22nd Mar 20245:33 pmRNSTransaction in Own Shares
22nd Mar 20242:08 pmRNSNet Asset Value(s)
21st Mar 20245:29 pmRNSTransaction in Own Shares
21st Mar 202412:51 pmRNSNet Asset Value(s)
20th Mar 20245:37 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.